Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
AKYNZEO IV (Mundipharma Pty Ltd)
Product name
AKYNZEO IV
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
172 working days (255)
Active ingredients
fosnetupitant chloride hydrochloride
Registration type
EOI
Indication
New Combination
AKYNZEO IV (powder for injection) is indicated for:
- The prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.
- The prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.